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Management of complex symptoms  
in multiple sclerosis (MS) 
people with ms can present with a 
complex range of symptoms. some 
of these include dysautonomia 
(autonomic dysfunction), fatigue, 
cognitive impairment, and mood 
disorders. these symptoms must 
be managed in order to optimise 
intervention outcomes. 
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2.0 Impaired thermoregulation
1.0 Dysautonomia or autonomic dysfunction 
Dysautonomia describes a range of disorders  
of the autonomic nervous system (ANS), and thus,  
may otherwise be known as autonomic dysfunction. 
There are three components to the ANS ― the 
sympathetic, parasympathetic, and enteric nervous 
system. The ANS controls unconscious body functions 
such as heart rate, temperature regulation, blood 
pressure, micturition (voiding urine), respiratory rate, 
and sexual function. 
In MS, the ANS changes are most commonly due 
to central nervous system (CNS) lesions from 
demyelination and axonal loss within the critical 
pathways responsible for autonomic function of spinal 
cord, brainstem, and hypothalamus. Demyelination 
and axonal loss may also occur within the cerebral 
cortex, including structures of the central autonomic 
network.1 Dysautonomia can affect single or multiple 
ANS functions depending on the location of the 
2.1 Incidence and impact
The incidence of impaired thermoregulation in people 
with MS is reported to be between 60 and 90%.3,4 
Thermoregulation may be critical for people with MS 
since even a small elevation of body temperature 
causes reduced nerve conduction velocity. This may 
enhance existing MS symptoms or accentuate new 
symptoms that were previously not apparent. In 
contrast, a reduction in nerve conduction velocity 
may also be beneficial as it may provide relief from 
pain symptoms. Therefore a person whose primary 
MS symptom is pain may want to exercise in a way 
that elevates body temperature. It is important to 
gain a thorough understanding of how impaired 
thermoregulation affects a person with MS, and  
to prescribe management strategies tailored to  
the individual.3
2.2 Clinical characteristics
Impaired thermoregulation presents as inappropriate 
increases or decreases in body temperature. The 
person with MS can be adversely affected by small 
changes in internal or external temperatures. A 
heightened response to increases in temperature is 
commonly referred to as ‘heat sensitivity’. Such an 
increase in temperature may occur during exercise, 
after a warm shower or bath, or when the person with 
MS has an infection. The increase in temperature 
can result in the onset or worsening of neurological 
symptoms, such as blurred vision, weakness or fatigue. 
2.3 Assessment
As mentioned, tests for assessment of ANS dysfunction 
are limited in value as they measure the organ involved 
rather than its response.5
2.4 Management
All factors that increase body temperature must 
be identified and managed according to the 
individual needs of the person with MS. Exercise is 
not contraindicated in the majority of people with 
thermoregulatory impairment, but care must be 
taken to minimise core body temperature elevation. 
It is recommended that 30 minutes of rest following 
exercise should allow symptoms to return to baseline. 
nervous system damage. While there is no cure for 
dysautonomia, the symptoms can be managed and 
their impact on an individual’s life reduced. The ANS 
may also be influenced by psychological factors such 
as depression and stress. These psychological factors 
need to be managed with psychological therapy to 
minimise their impact on the ANS.2 The relationship 
between ANS dysfunction and these symptoms is weak. 
Further research is required to support or refute the 
involvement of the ANS. 
Health professionals who suspect that a person  
with MS has dysautonomia should refer them to  
their neurologist for testing and management. A 
number of reliable tests are available to identify 
dysautonomia. However, they can be difficult to 
interpret because they test the organ function rather 
than the organ innervation. 
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Symptom changes that last longer than this may 
temporarily impair the person’s function.6 For example 
exercise induced onset of blurred vision, or increased 
numbness in the lower limbs, may temporarily impact 
on a person’s driving ability. Exercise intensity should 
be managed, and cooling strategies used to avoid 
prolonged post-exercise symptom increase. 
It is important to note that an increase in symptoms 
that persist for 24 hours or more, post-exercise, may  
be related to a coincidental MS relapse. In this 
situation the patient should be referred to their  
medical practitioner for appropriate management  
and advice. Accurate recording of symptoms, pre-  
and post-exercise, will support decision making in  
this instance.
The following suggestions may assist people with MS to 
curtail rises in core body temperature during exercise:
n Wearing loose, light clothing
n Maintaining hydration by drinking cool water before, 
during, and after exercise
n Exercising in a cool environment (e.g., morning or 
evening; air-conditioned room; pool heated up to 
27°C for those affected by heat [the temperature 
may be up around 32°C])
3.1 Incidence and impact
Cardiovascular dysfunction will affect 10–50% of 
people with MS. The pattern of pathological findings 
is highly heterogeneous, suggesting a predominantly 
sympathetic involvement in some patients, and a 
predominantly parasympathetic pathology in others.5 
These impairments may be related to the number of 
lesions within the mid-brain.10 The overall impact of 
cardiovascular dysfunction in MS is unknown; it may 
affect the safety of exercise participation.
3.2 Clinical characteristics
Cardiovascular dysfunction in people with MS may 
involve reduced heart rate response11,12 and blood 
pressure response to stimuli such as exercise and 
stress.13 Self-reported symptoms may include postural 
hypotension, dizziness, and light headedness which 
can impact on the person’s ability to maintain balance, 
or move around their environment.5 
n Avoiding exercise in direct sunlight
n Exercising regularly for short periods, rather than 
less frequently for long periods 
n Wearing a wet towel or cooling scarf around  
the neck 
n Having a cool shower after exercising
n Wearing a cooling vest immediately prior,  
during, and after exercise 
n Not exercising if unwell.
Cooling therapy may be indicated for individuals with 
severe heat intolerance. Cooling therapy involves 
reducing surface body temperature to  
10-20°C. research is limited in this area. However 
it demonstrates a trend; supporting the use of 
cooling therapy to reduce body temperature and 
improve nerve conduction (for up to 30 minutes), with 
symptom reduction continuing throughout the day of 
intervention. Cooling therapy is complicated and should 
only be undertaken by a health professional who 
specialises in MS and has appropriate training.7–9 
3.0  cardiovascular dysfunction
3.3 Assessment and management
people with MS should be assessed for their response 
to exercise prior to prescribing cardiovascular exercise. 
This involves taking regular heart rate and blood 
pressure measurements. If these measures show a 
blunted response to exercise, alternative measures 
such as Borg rate of perceived Exertion scale should 
be used to monitor training exercise intensity. people 
with a history of falling should also be screened for 
orthostatic intolerance.5 people with MS who have any 
cardiovascular risk factors should undertake formal 
cardiovascular fitness testing prior to engaging in 
stressful cardiovascular physical activities. For further 
information refer to the Strength and cardiovascular 
exercise for people with multiple sclerosis handout.
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4.1 Incidence and impact
Sleep disturbance is reported to affect between 
45 and 60% of people with MS. It is related to a 
combination of factors such as: sleep-related breathing 
disturbances, immobility, leg muscle spasms, pain, 
nocturia, medications,14,15 restless leg syndrome 
(rlS)16, and psychological issues such as anxiety and 
depression.17,18 Frequent night-waking can affect a 
person’s ability to function the following day. Nocturia 
(the need to get up during the night in order to urinate) 
was reported as the primary reason for middle-of-the-
night insomnia.14 Another significant sleep disorder in 
people with MS is narcolepsy.19 Narcolepsy is a chronic 
neurological disorder in which the brain is unable to 
regulate normal sleep–wake cycle, leading to fleeting 
urges to sleep. Both sleep issues have the potential 
to cause daytime fatigue and somnolence (excessive 
daytime sleepiness). Middle-of-the-night insomnia, 
rather than initial or terminal insomnia, is highly 
correlated with fatigue and somnolence. 
5.1 Incidence and impact
The reported incidence of bladder voiding dysfunction 
in people with MS ranges between 30 and 50%, and 
appears to be related to disease disability status.20,21 
Lack of bladder control can significantly limit a 
person’s quality of life. Many people reduce their 
activity participation because of the risk of social 
embarrassment, and fear of being unable to access 
toileting facilities.
5.2 Clinical characteristics
Detrusor-sphincter dyssynergia and detrusor hyper-
reflexia (overactivity) are two bladder dysfunctions 
that occur in people with MS. They are indicative of a 
pontine and cervical spinal cord lesion, respectively.21 
Detrusor-sphincter dyssynergia is loss of coordination 
between the detrusor and external urethral sphincter 
(outlet obstruction). This results in urinary retention 
(incomplete emptying) and may lead to upper urinary 
tract dilation, chronic renal failure, or urinary tract 
infection. Detrusor hyper-reflexia is involuntary bladder 
contraction which produces the sensation of imminent 
voiding (urgency) despite low bladder volume. 
urge incontinence occurs when these involuntary 
contractions are associated with urine leakage.5,13 
5.3 Assessment
Health professionals should screen people with MS for 
bladder dysfunction during subjective examinations 
and strongly encourage people with bladder issues 
to access appropriate services. people with these 
symptoms should be referred to an MS nurse (1800 
042 138), urologist, or to the Continence Foundation of 
Australia (www.continence.org.au or 1800 330 066).  
5.4 Management
Management of bladder dysfunction is important to 
prevent chronically raised temperatures and long-
term health issues. optimal management of bladder 
overactivity and incomplete bladder emptying may 
involve anticholinergic medication and intermittent 
catheterisation. Note that catheterisation may be 
difficult for people with upper limb dysfunction, 
spasticity, weakness, poor sitting balance, or cognitive 
4.2 Clinical characteristics
Common clinical signs of sleep disturbance are fatigue 
(prior to physical or mental exertion), somnolence, 
irritability, and difficulty with concentration. 
4.3  Assessment and management
Health professionals may identify people with 
sleep disturbance during subjective examinations. 
Management is dependent on the cause of the sleep 
disturbance. referral to an MS nurse (1800 042 138) 
or other relevant health professionals for assessment, 
strategies and medication to manage the MS 
symptoms that are affecting their sleep (e.g., bladder 
dysfunction, depression, pain, spasticity, narcolepsy, 
and RLS), may be of benefit. Referral to a sleep clinic 
for formal sleep studies should be considered for 
people who continue to have sleep disturbances. 
4.0 Sleep dysfunction
5.0 Bladder dysfunction
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impairment. urgency and incontinence may become 
refractive to medication and require management 
with an indwelling catheter (suprapubic or urethral).22 
physiotherapists have a role in maintaining adequate 
physical function to allow people to manage these 
issues themselves. If incontinence continues in the 
absence of abnormal bladder volumes, there may be 




6.1 Incidence and impact
The incidence of bowel dysfunction in people with 
MS ranges from 45–68% with a higher incidence 
correlated with longer disease duration.24 The impact 
of bowel dysfunction can be similar to that of bladder 
dysfunction, affecting quality of life, and activity 
participation. 
6.2 Clinical characteristics
Bowel dysfunction may involve gastroparesis (impaired 
stomach motility), abnormal colonic motor activity, or 
anorectal dysfunction, which results in the symptoms 
of constipation and/or faecal incontinence.
6.3 Assessment and management
As with bladder dysfunction, health professionals 
should regularly screen people with MS for bowel 
7.1 Incidence and impact
Autonomic dysfunction can cause sexual dysfunction in 
men and women with MS. One recent study identified 
61% of its MS female population to report some sexual 
dysfunction25 and 80% of the MS male population.26 
This may result in difficulty with fertility, sexual 
pleasure, and impaired sexual relations. 
7.2 Clinical characteristics
Sexual dysfunction may be related to autonomic 
dysfunction or MS symptoms. Autonomic dysfunction 
can cause impotence (erectile dysfunction) in men, 
and alter orgasmic capacity in both men and women.26 
Women may also experience decreased lubrication, 
sensory dysfunction in the genital area, weakness of 
the pelvic muscles, decreased sexual desire and lower 
dysfunction during subjective examinations. They 
should strongly encourage those with bowel issues 
to access appropriate services. For professional 
assessment and management, people should be 
referred to an MS nurse (1800 042 138) or to the 
Continence Foundation of Australia (www.continence.
org.au or 1800 330 066). Management strategies to 
address constipation in people with MS may involve 
ensuring sufficient daily fluid intake, recommendations 
for a high fibre diet, prescription of regular physical 
activity, and a daily routine of attempted evacuation 
(with or without the assistance of suppositories and 
medications).13
 
libido.25 other symptoms experienced by people with 
MS that can interfere with a normal sexual response 
include somatosensory loss (e.g., vibration sense loss), 
bowel and bladder dysfunction, fatigue and muscular 
impairment. Sexual intimacy is compounded further by 
potential psychological factors such as low self-esteem, 
mood, and coping with disability.
7.3 Assessment and management 
Medical practitioners have a key role in 
pharmacological management of sexual dysfunction 
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in people with MS. other health professionals may 
become involved in managing related symptoms 
that are affecting sexual function. There is emerging 
evidence for the role of physiotherapists in the 
provision of pelvic floor exercises to reverse muscle 
weakness. Muscle weakness of the pelvic area may be 
inversely linked with male and female genital arousal 
and orgasm.27
Fatigue is a difficult symptom to define as people 
experience fatigue in different ways, and because 
the causes and mechanisms of MS fatigue remain 
somewhat unclear.28 The Fatigue Management panel 
of the Multiple Sclerosis Council for Clinical practice 
Guidelines defines fatigue as “a subjective lack of 
physical or mental energy that is perceived by the 
individual or caregiver to interfere with usual and 
desired activities.”29
Fatigue is related to a number of causative factors and 
is commonly referred to as either primary or secondary. 
primary fatigue is attributed to the intrinsic MS disease 
process and is evidenced when fatigue is worsened 
by heat. Secondary fatigue occurs as a result of other 
MS symptoms (e.g., disturbed sleep, pain, or spasms), 
medications. It is also a consequence of inactivity 
and is similar to that experienced in the general 
population.30 Fatigue is often reported in people 
with MS in conjunction with subjective symptoms of 
depression and cognitive disturbances. While fatigue 
is often a reported symptom of depression, MS related 
fatigue can be independent of clinical depression.
Differential testing will be required to establish 
causative association and appropriate management.31 
recently, depression was demonstrated to have a 
moderate link with fatigue ― especially cognitive fatigue 
as measured by the Modified Fatigue Impact Scale.32 
However, fatigue symptoms are not related to tested 
and confirmed cognitive impairment.33  
8.1 Incidence and impact
The symptom of fatigue is reported to affect 75% of 
people with MS at some stage during the course of 
their illness.31,34–36 In comparison, between 20 and 
25% of the general population report feeling tired all 
the time.37 Fatigue may impact significantly on physical 
functioning and quality of life. 
8.2 Clinical characteristics
There are characteristics of MS-related fatigue which 
distinguish it from the sort of fatigue experienced by 
healthy individuals:
n It generally occurs on a daily basis
n Its onset occurs more easily and suddenly
n Its onset occurs more easily after daily activities, 
and necessitates resting 
n It tends to be aggravated by heat and humidity
n It is more likely to interfere with daily 
responsibilities.
8.3 Assessment
The assessment of fatigue is best undertaken by a 
suitably experienced allied health professional. They 
can screen for primary and secondary causes of fatigue 
during a subjective assessment. Subjective self-report 
measures are usually more practical for the clinical 
setting.37 A range of subjective and objective fatigue 
measures are available:
n Fatigue Severity Scale (FSS)38
n Fatigue Assessment Instrument39
n Fatigue Impact Scale (FIS) or Modified Fatigue 
Impact Scale (MFIS)40
n Single item visual analogue scale of fatigue38
n rochester Fatigue Diary.41
of these tools the FSS, FIS, and MFIS have been 
validated for use in a population of people with MS.38,40 
It is noted in clinical practice that as people improve 
their overall functional capacity, they undertake more 
activity participation. This automatic increase in activity 
can distort measurements of response to fatigue 
8.0 Fatigue
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management interventions as people continue to 
complain of similar levels of fatigue. Keeping an activity 
diary may help to identify these people. 
8.4 Management
The management of fatigue requires a multidisciplinary 
approach.42 once potential causal factors have been 
identified, referrals to the appropriate services and 
specialists ― such as psychology, physiotherapy, 
continence advice, sleep clinics, medical specialists, 
social worker, or dietician ― can be arranged. The 
following management guidelines are based on the 
fatigue management guidelines published by the 
Multiple Sclerosis Council for Clinical practice.29
8.4.1 Energy conservation
occupational therapists and other health professionals 
can educate people with MS, their families and carers 
about balancing rest and activity through prioritising, 
delegating, pacing tasks, and taking regular short rests 
between tasks. people with MS-related fatigue can 
learn how to identify aggravating lifestyle factors and 
apply the aforementioned strategies as their activities 
change and as the effects of fatigue  
vary over time.43,44
8.4.2 Exercise
people with MS participate in less physical activity 
and adopt a more sedentary lifestyle as a result of 
MS-related symptoms.45 The combination of reduced 
physical activity and MS fatigue symptoms can lead to 
a progressive disuse cycle whereby lower activity levels 
lead to reduced physical fitness. This increases the 
energy costs of physical activity and worsens fatigue 
symptoms. Worsening fatigue then leads a person to 
further reduce their physical activity, continuing the 
progressive cycle. This cycle can be interrupted through 
regular exercise utilising physiotherapy rehabilitation 
interventions.46,47 The aim of these interventions is to 
increase the efficiency of energy utilisation throughout 
the body in order to reduce the energy cost of activity 
which should reduce secondary fatigue.48 
practical strategies for providing exercise and 
treatment sessions for a person with MS who is 
affected by fatigue:
n Scheduling the exercise or treatment sessions early 
in the day
n Encouraging the person to work at their own pace 
and have regular rests
n Beginning with exercise sessions of short duration 
(<20 minutes) and gradually increasing as tolerated
n Beginning with a low number of repetitions and 
low intensity then gradually progressing as the 
participant can manage more repetitions or 
increased intensity
n Mixing vigorous exercises with lighter exercises to 
avoid long periods of exercise at high heart rates
n Alternating muscle groups in order to rest one 
muscle group while exercising another
n Encouraging the participant to maintain regular fluid 
intake to avoid dehydration 
n Encouraging the participant to keep body 
temperature down as much as possible.
8.4.3 Equipment modifications
occupational therapists and physiotherapists  
can prescribe and train people with MS to use  
assistive equipment for mobility, self-care, and seating. 
This can minimise energy consumption during activities 
of daily living. Supportive seating can reduce energy 
consumption for maintaining posture, and mobility 
equipment may improve the biomechanical efficiency 
of walking, thus reducing fatigue associated with 
walking.49–51
8.4.4 Environmental modifications
Changes to environmental factors can assist in 
minimising fatigue. Changes may include installing 
air-conditioning, elevators, railings in stairwells, and 
ergonomic office equipment. An assessment and 
appropriate recommendations can be made by a 
physiotherapist or occupational therapist to improve 
the workplace or the home environment.
A multidisciplinary team may address additional factors 
such as sleep disturbance, spasms, pain, nocturia, 
medication side effects, or breathing disturbances. 
pharmacological intervention may be prescribed when 
adequate improvement has not been achieved using 
the aforementioned fatigue management strategies. 
Medication is not widely used in Australia for MS-
related fatigue management compared with other parts 
of the world. However, medications that may be used 
to manage MS-related fatigue include amantadine, 
modafinil, pemoline, and methylphenidate. Some of 
these medications have reported side effects such 
as irritability, insomnia, hyperactivity, dry mouth, 
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constipation and urinary retention.37 It is important for 
people with MS to discuss the use of these medications 
with their general practitioner, neurologist, and 
pharmacist to ensure that side effects and potential 
drug interactions are minimised. 
9.0  cognitive impairment
9.1 Incidence and impact
Cognitive impairment (i.e., memory and thinking 
problems) may occur in more than 50% of people 
with MS.52 participation in work, social and home 
environments can be significantly affected by the 
presence of any of these cognitive impairments. 
9.2 Clinical characteristics
Cognitive impairments in people with MS most 
commonly involve short-term memory, attention,  
speed of information processing, and executive 
function (such as abstract reasoning, problem-solving, 
self-monitoring insight and flexibility of thought). 
Some of these impairments may be apparent during 
daily tasks, such as holding a conversation within a 
distracting environment, doing two things at once, or 
completing complex work tasks. The capacity to be 
aware of one’s own cognitive impairment can, itself, be 
impaired in some people with MS. It should be noted 
that cognitive impairment is not correlated with disease 
duration or with severity of physical symptoms.53 
Cognitive impairment tends to be mild to moderate 
in most people with MS, but in approximately 10% of 
people with MS, it can become severe enough to be 
classified as a form of MS-related dementia.54
9.3 Assessment
Health professionals often rely on a person’s  
verbal report or demonstration of cognitive impairment 
to guide intervention decisions and accommodate 
the person’s cognitive status. Cognitive impairments 
in MS are notoriously difficult to detect during brief 
social interactions and verbal self-reports may be 
influenced by symptoms other than cognitive issues.55 
For example, people with MS who have depression55 
or fatigue33 tend to self-report higher levels of 
cognitive impairment than is evident through testing. 
Furthermore, some people with MS who have cognitive 
impairment may not be aware of it themselves, and will 
therefore not necessarily report it.56
If cognitive impairment is suspected, a thorough 
understanding of a person’s cognitive impairments 
through a neuropsychological assessment can assist. 
Health professionals and their clients can set realistic 
goals, and maximise adherence with treatment plans 
and intervention outcomes. Whenever cognitive 
impairment is suspected, and especially when people 
with MS report that suspected cognitive impairment 
is impacting upon their work or their ability to live at 
home, a neuropsychological assessment should be 
sought. If the presence of cognitive impairment is less 
obvious, a referral to an occupational therapist trained 
in screening people with MS for cognitive impairment 
may assist in clearly identifying if there is any cognitive 
impairment. An occupational therapist can also provide 
practical advice about the management of cognitive 
symptoms. 
9.4 Management 
Scientific evidence for the effectiveness of 
psychological interventions to assist people with MS, 
and to specifically manage cognitive impairments, 
is currently inconclusive.56–58 There is, however, 
an increasing number of encouraging studies 
showing evidence for the effectiveness of cognitive 
rehabilitation in MS.59,60 No medication has shown a 
stand-alone capacity to clinically improve symptoms 
of cognitive impairment in people with MS.56,61 A small 
single-centre trial recently demonstrated that donepezil 
has promising benefits for improving memory, but 
further studies are required to confirm this finding.62 
A recent study exploring the role of modafinil in the 
treatment of cognitive impairment is also showing 
promise. Current management approaches focus 
on applying strategies that minimise the impact of 
cognitive impairment on a person’s ability to set 
realistic goals and manage daily tasks. 
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Basic strategies that health professionals can  
use to maximise therapy interventions (such as 
exercise classes, or fatigue management education 
sessions) include:
n Minimising background noise and distractions
n Exercising for shorter periods of time  
to accommodate reduced capacity to  
sustain concentration
n Ensuring that intervention sessions are  
well-structured, engaging, and reinforcing to help 
keep a disorganised person focused and clear 
about each session’s goals
n providing written, audio-taped, or video-taped 
instructions in addition to verbal instructions  
to take with them
n providing demonstration and/or manual  
guidance to facilitate understanding about the 
required movements when teaching manual  
tasks or exercises 
n providing people with MS with succinct written 
education materials to support their decision-
making regarding clinical treatment options63
n Scheduling multiple short consultations instead 
of fewer long consultations since people with MS 
have a greater susceptibility to cognitive fatigue and 
reduced learning capacity
n Speaking slowly and clearly to people with impaired 
information processing speed, allowing them time 
Mood disorders are common in MS, as are depressive 
and generalised anxiety disorders. They are:
n Major depressive disorder 
n Dysthymic disorder 
n Bipolar disorder
Major depressive disorder is the most common of these 
disorders and will be discussed further, along with 
anxiety disorder.
10.1 Major depressive disorder
10.1.1 Incidence and impact
Depression has been reported to affect between 
50 and 60% of people with MS at some stage 
during the course of the disease.68–70 At any one 
time, approximately 15–40% of people with MS will 
have depression.71 This rate of depression is higher 
than the rate of 15% reported in people with other 
to provide an appropriate response, and checking 
that they understand what they need to know before 
ending a session
n Encouraging the person to use a diary or calendar to 
improve recollection of appointments and important 
daily tasks (such as practising exercises)
n Allowing each new skill to be strongly established 
(using extra rehearsal time if necessary) before 
introducing new skills, in order to help reduce the 
impact of rigidity (cognitive inflexibility) or moderate 
memory impairment
n providing additional reviews of progress to ensure 
that intervention goals are being met and cognitive 
issues are not interfering with maintenance 
behaviours and exercise routines
n Considering the principles of Errorless learning,64 
Spaced retrieval learning,65 Story Memory 
Technique,66 or other training techniques shown to 
be effective in people with other forms of acquired 
brain injuries (such as stroke or traumatic brain 
injuries) for teaching important new skills to people 
with moderate memory impairment
n Ensuring close one-on-one supervision, feedback or 
guidance is provided to people who may be at risk of 
injury or falls during manual tasks. The supervision 
may be provided by training with a friend, relative, 
carer, or volunteer.
chronic illness72 or the non-MS healthy population.73 
Depression can affect all aspects of life participation 
and enjoyment.
10.1.2 Clinical characteristics and causes
Major depressive disorder is characterised by a 
persistently low mood, occurring most of the time, 
lasting for weeks or longer, and of sufficient severity to 
cause distress and/or affect social or work function. 
The low mood is usually accompanied by feelings of 
sadness or emptiness. people with depression often 
report a loss of interest and pleasure in daily activities 
and can feel worthless and guilty.74
10.0 Mood disorders
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The underlying cause of the much higher rate of 
depression in people with MS is poorly understood. 
Many studies have postulated associations or 
correlations; however for as many that found 
correlations others have not. Some possible  
causes are:
n uncertainty of disease progression75,76  
including future disability level77,78
n Medication side effects, notably interferon 1 beta 
has shown positive correlation79 and negative 
correlation68
n loss of social support and contact80
n Neurobiological influence from altered immune 
function, CNS lesions and abnormalities in 
hypothalamic functioning has shown both positive 
correlation76 and negative correlation81 with 
depression
n post-traumatic stress reactions to the diagnosis 
and to living with a chronic, potentially deteriorating 
condition.82
Depression in people with MS should be identified  
and treated swiftly since 30% of people with MS  
with concomitant depression report suicidal intent.83 
Suicidal intent is three times greater than an age-
matched population,76,83 and untreated depression 
worsens over time.84 Depression also significantly 
affects quality of life42,85–88 and may even worsen the 
underlying pathogenic inflammatory processes  
of MS.89 
10.2 Assessment
When a health professional suspects that a person 
has depression, they should encourage them to accept 
a referral to a clinical psychologist or mental health 
professional to undergo a full assessment and receive 
appropriate intervention. Two studies have suggested 
that regular use of depression screening questions may 
be of benefit to the health professional. The screening 
questions consist of:
1.  “Are you depressed?”90
• An affirmative answer warrants referral 
to a clinical psychologist
2a. “During the past two weeks, have you often been 
bothered by feeling down, depressed, or hopeless?”
2b. “During the past two weeks, have you often been 
bothered by little interest or pleasure in doing 
things?” 
• An affirmative answer to one of these questions 
warrants a referral to a clinical psychologist.91 
10.3 Management of depression
The treatment of depression may improve an 
individual’s self-esteem, functional status, quality 
of life, and overall compliance to medical and 
rehabilitation programs.57,92 Cognitive behavioural 
therapy is demonstrated to significantly improve 
depression, anxiety, and coping with MS.57 This is 
especially true for mild to moderate depression. other 
interventions include the use of antidepressants84 
and improved social supports and contacts. The use 
of exercise as an adjunct to clinical psychology for the 
improvement of depression in MS has been poorly 
investigated. To date, findings have not supported 
exercise in its own right as beneficial in improving 
depression in people with MS.93 More studies are 
needed with larger numbers of participants or involving 
cognitive behavioural therapy. 
11.0 anxiety disorder
11.1 Incidence and impact
Anxiety disorders are reported to affect between 37  
and 40% of people with MS,94,95 and are associated 
with social dysfunction and thoughts of suicide.83 
Individuals with anxiety disorder may also have a major 
depressive disorder.95 Anxiety is commonly noted in 
people with a recent diagnosis of MS,96 and is often  
related to post-traumatic stress reactions to the  
diagnosis, and to living with a chronic, potentially 
deteriorating condition.82
11.2 Assessment and management
people with anxiety disorder should be referred to a 
clinical psychologist for appropriate management. 
Evidence points strongly to an increase in MS relapses 
when a person with MS experiences multiple stressors 
or stress without social supports. These stressors 
appear to be related to everyday events rather than 
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disease activity.97–99 Emotional stressors include 
depression, anxiety, negative attributions (negative  
self-talk or beliefs), inability to cope, and low 
social support.100
limited research has been conducted on people 
with MS to ascertain responses of anxiety disorders 
to pharmaceutical and psychotherapy management 
techniques. However the evidence is clear that 
depression and anxiety are comorbid conditions, and 
successful treatment of one benefits the state of the 
n people with MS can present with a complex range of 
symptoms, such as dysautonomia, fatigue, cognitive 
dysfunction, continence problems, and mood 
disorders. These symptoms can affect the success 
of health professional interventions and must be 
suitably managed in order to optimise intervention 
outcomes.
n Dysautonomia refers to disorders of the ANS 
and can cause impaired thermoregulation, 
cardiovascular dysfunction, sleep disturbance, 
bladder voiding dysfunction, bowel dysfunction, and 
sexual dysfunction in people with MS.
n Many of the symptoms of dysautonomia can be 
managed (though not cured) by the involvement 
of a range of health professionals such as 
nurses, doctors, occupational therapists, and 
physiotherapists. 
n Fatigue affects up to 75% of people with MS and 
can be either primary (attributed to the intrinsic MS 
disease process) or secondary (e.g., a consequence 
of inactivity). Depression has been shown to be a 
moderate causative factor of MS cognitive fatigue. 
n Fatigue can severely limit a person’s ability 
to function and participate in many activities. 
Effective multidisciplinary management strategies 
can address depression (when evident), energy 
other. It is also clear that cognitive behavioural therapy 
for anxiety is the most effective approach among the 
general population. There is strong evidence that the 
psychological outcomes of people with MS are more 
closely related to controllable cognitive and behavioural 
factors than to the physical effects of the disease. 
Consequently, it can be concluded that interventions 
that target these specific coping strategies and 
cognitive appraisals, such as cognitive behavioural 
therapies, will be effective in treating the emotional 
effects of MS.101
conservation, exercise, equipment modification, 
environmental modification and other factors such 
as sleep disturbance and muscle spasms. 
n Cognitive dysfunction occurs in approximately 
50% of people with MS and can involve impaired 
short-term memory, attention, speed of information 
processing, and executive functioning. This area 
of symptomatology can affect a person’s capacity 
to set realistic goals and adhere to agreed 
rehabilitation programs, as well as affecting their 
performance of social and work tasks. 
n Neuropsychological assessment can help to 
identify and clarify the nature and potential 
practical implications of various types of 
cognitive impairment. A neuropsychologist can 
also recommend strategies for overcoming this 
impairment. This information and advice can assist 
health professionals to deliver services to a person 
with MS who is cognitively impaired in a way that is 
realistic and effective in supporting their goals.
n people with MS have a high risk for  
depression (50–60%), anxiety (37–40%),  
and suicidal intent (30%). 
n people with MS who have symptoms of depression 
or anxiety should be referred to a clinical 
psychologist for assessment and management.
12.0 Summary
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